Skip to content

Study of Transverse Abdominis Plane (TAP) Block in Children Undergoing Hydrocelectomy and/or Hernia Repair Surgery

The Efficacy of Transverse Abdominis Plane (TAP) Block in Children Undergoing Hydrocelectomy and/or Hernia Repair

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01698268
Acronym
TAP
Enrollment
50
Registered
2012-10-02
Start date
2012-02-29
Completion date
2014-11-30
Last updated
2017-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hydrocele, Inguinal Hernia

Brief summary

Study measures the difference in pain after hernia &/or hydrocele repair based on site of local anesthesia injection.

Detailed description

This single-center, prospective, single blind, randomized study will enroll up to 50 subjects who are scheduled for elective hydrocelectomy and/or hernia repair. At Beaumont Health System, post-operative pain management in children is managed either via oral/parenteral opiates and opiate adjuncts, surgeon-administered field blocks (instillation of local anesthetics in the general area of incision), or via regional techniques (spinal, epidural, or peripheral nerve blocks). We have designed this study to determine if there is improved qualitative and quantitative post-operative pain control in patients receiving TAP block versus intraoperative peri-incisional, surgeon administered field block. Once informed consent has been given, each patient will be randomized (like flip of the coin) to either Transverse Abdominis Plane Block (TAP Block)or surgeon administered anesthesia.

Interventions

PROCEDURETAP block

TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.

PROCEDURELocal Infiltration

Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.

Sponsors

Kaveh Aslani, MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
2 Years to 8 Years
Healthy volunteers
No

Inclusion criteria

* Children 2-8 years of age * Elective inguinal hernia repair, inguinal hernia repair with peritoneoscopy and/or hydrocelectomy to be performed in the Center for Children's Surgery, Beaumont Hospital, Royal Oak * American Society of Anesthesiologists physical status classification 1 and 2 (patients that have either no systemic illness, or mild systemic disease that is well controlled, eg. mild asthma)

Exclusion criteria

* History of allergy to study medications * Enrollment in concurrent research study * Pregnant patients\* * Students/trainees/staff\* * Mentally disabled/cognitively impaired\*

Design outcomes

Primary

MeasureTime frameDescription
FLACC: Face, Legs, Activity, Cry, and Consolability Pain Assessment Scale (FLACC)Admission into PACUFLACC: Face, Legs, Activity, Cry, and Consolability Pain Assessment Scale (FLACC), a five-item, three point scale that measures pain behavior on a scale of 0 - 2 which are summed to result in a total score of 0 - 10. Clinical judgment is used to interpret pain. The higher the score on the FLACC correlates with a higher pain score (0= no behaviors indicative of pain and 10= five behaviors indicative of significant pain). This scale was evaluated by blinded post-operative anesthesia care unit (PACU) Registered Nurses (RNs) at admission to PACU.

Countries

United States

Participant flow

Recruitment details

This single-center, prospective, single blind, randomized study enrolled subjects who were scheduled for elective hydrocelectomy and/or hernia repair at Beaumont Hospital-Royal Oak. The first procedure was on 3/16/2012 and the last one was on 11/12/2014.

Participants by arm

ArmCount
TAP Group
Enrolled subjects will receive a TAP block with 0.5cc/kg of 0.25% ropivacaine. TAP block: TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
23
Local Infiltration Group
Enrolled subjects will receive will receive local infiltration of 0.5 cc/kg of 0.25% ropivacaine. Local Infiltration: Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
24
Total47

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPhysician Decision21

Baseline characteristics

CharacteristicTAP GroupLocal Infiltration GroupTotal
Age, Categorical
<=18 years
23 Participants24 Participants47 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Region of Enrollment
United States
23 Participants24 Participants47 Participants
Sex: Female, Male
Female
3 Participants3 Participants6 Participants
Sex: Female, Male
Male
20 Participants21 Participants41 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 230 / 24
other
Total, other adverse events
9 / 237 / 24
serious
Total, serious adverse events
0 / 230 / 24

Outcome results

Primary

FLACC: Face, Legs, Activity, Cry, and Consolability Pain Assessment Scale (FLACC)

FLACC: Face, Legs, Activity, Cry, and Consolability Pain Assessment Scale (FLACC), a five-item, three point scale that measures pain behavior on a scale of 0 - 2 which are summed to result in a total score of 0 - 10. Clinical judgment is used to interpret pain. The higher the score on the FLACC correlates with a higher pain score (0= no behaviors indicative of pain and 10= five behaviors indicative of significant pain). This scale was evaluated by blinded post-operative anesthesia care unit (PACU) Registered Nurses (RNs) at admission to PACU.

Time frame: Admission into PACU

ArmMeasureValue (MEDIAN)
TAP GroupFLACC: Face, Legs, Activity, Cry, and Consolability Pain Assessment Scale (FLACC)0 units on a scale
Local Infiltration GroupFLACC: Face, Legs, Activity, Cry, and Consolability Pain Assessment Scale (FLACC)0 units on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026